Research Article Details
| Article ID: | A18034 |
| PMID: | 27394182 |
| Source: | Clin Chim Acta |
| Title: | Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults. |
| Abstract: | BACKGROUND: Lipoprotein(a) [Lp(a)] and nonalcoholic fatty liver disease (NAFLD) are risk factors for cardiovascular diseases. We investigated the relationship between Lp(a) concentrations and NAFLD among Korean adults. METHODS: A total of 2242 nondiabetic subjects undergoing routine health screening examination were enrolled. Anthropometric and biochemical parameters, including Lp(a) were measured. NAFLD were assessed by ultrasonography. Adjusted Odds ratios for the presence of NAFLD according to Lp(a) tertiles were estimated using logistic regression. RESULTS: Subjects were grouped according to the severity of NAFLD and Lp(a) concentrations. Lp(a) concentrations were decreased across the severity of NAFLD and the prevalence of NAFLD decreased with the Lp(a) tertiles. Compared with subjects in the lowest tertile of Lp(a), those in the highest tertile had higher total cholesterol and LDL-C concentrations and lower body mass index, blood pressure, fasting glucose, triglyceride, ALT, and HOMA-IR concentrations. In the logistic regression analysis after adjusting for multiple risk factors, the relationship between Lp(a) concentrations and the presence of NAFLD remained significant. However, this association was attenuated after adjusting for insulin resistance. CONCLUSIONS: Lp(a) was inversely associated with the presence of NAFLD, but it was not an independent risk factor for NAFLD among Korean adults. |
| DOI: | 10.1016/j.cca.2016.07.003 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |